FilingReader Intelligence
Henlius begins US phase 2 lung cancer trial
August 22, 2025 at 09:17 AM UTC•By FilingReader AI
Henlius has dosed the first US patient in an international phase 2 trial of HLX43, an anti-PD-L1 antibody-drug conjugate for advanced non-small cell lung cancer.
The trial is also running in mainland China, with Australia and Japan planned. Phase 1 trials showed encouraging anti-tumor activity and favorable safety.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime